Hot topics
Molecular phenotyping of severe asthma
Translational
the role of consortia in driving personalised medicine
Aims : To describe how severe asthma consortia have improved our knowledge of how molecular phenotypes may be linked to clinical features; to define how severe asthma phenotypes vary across the globe; and to outline how integration of the data across consortia will lead to better drugs for selected patients.
Target audience :
Allergologist, Clinician, Epidemiologist, General practitioner, Immunologist, Junior member, Nurse, Paediatrician, Pathologist, Patient, Pharmaceutical industry representative, Pulmonologist, Researcher, Resident, Respiratory physician, Scientist, Student, Trainee
14:45
SARP: redefining our knowledge of severe asthma
S. Wenzel(Pittsburgh, United States)
COI
1
4529
15:15
Novel aspects of severe asthma from BIOAIR
S. Dahlén(Stockholm, Sweden)
COI
2
4530
15:45
Severe asthma in Asia: insight into phenotypes
T. Kim(Seoul, Republic of Korea)
COI
3
4531
16:15
Data integration: the way to personalised treatment in severe asthma
P. Sterk(Koudekerk aan den Rijn, Netherlands)
COI
4
4532
. . .
